DuPont De Nemours (DD) has been making significant strides, with valuation gaining steam after the launch of healthcare and water solutions products. Achieving a 36% one year share price gain, the company also reported a one-year return that skyrocketed after a 3.6% gain last week. DD has also invested in a sustainability target for 2035, contributing to its digital growth potential. Meanwhile, a surge in share prices has investors questioning if it’s too late to invest.
The company has launched new pharma assemblies, intending to cut leaks and setup time. Wall Street has a promising Q4 outlook for DD, with estimates on key metrics. DuPont's dividend and board shift alongside the introduction of new healthcare resins have altered its investment story. DuPont has received an outperform rating from RBC Capital, meanwhile, options market predicts a spike in the company's stock. The company also upgraded its water treatment software amid growing demand, benefiting its market positioning.
However, DD's disappointing earnings and one-off US$577 million loss have tested the bullish margin narrative. Yet, amidst these challenges, DD's transformation process is almost complete with the reshaping of its aramid sale portfolio and raising valuation questions.
The company saw a 52% drop and underwent industry restructuring in 2025 that might affect its performance. On a positive note, DD's Q3 2025 earnings called attention to strong organic growth. Nevertheless, despite all these, Jim Cramer still advises not to sell DD.
Dupont De Nemours DD News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Fri, 24 Apr 2026 19:35:40 GMT - Rating 6 - Innovation 6 - Information 9 - Rumor 0
